1,660 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by R Squared Ltd

R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,660 shares of the biopharmaceutical company’s stock, valued at approximately $757,000.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the period. Geode Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Orbis Allan Gray Ltd grew its holdings in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares during the period. Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $662,837,000. Finally, American Century Companies Inc. increased its position in shares of Alnylam Pharmaceuticals by 1.9% in the second quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock valued at $584,957,000 after buying an additional 33,411 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 9,577 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the transaction, the chief executive officer owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. The trade was a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,959 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the completion of the sale, the executive vice president directly owned 31,769 shares of the company’s stock, valued at $9,850,931.52. This trade represents a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,578 shares of company stock valued at $12,416,105 in the last 90 days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $331.24 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The firm has a market capitalization of $43.93 billion, a PE ratio of 193.71 and a beta of 0.35. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The firm’s 50-day moving average price is $361.89 and its 200 day moving average price is $419.66.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period last year, the business earned ($0.65) earnings per share. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Needham & Company LLC decreased their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Wells Fargo & Company reduced their price target on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. Finally, Jefferies Financial Group decreased their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.